12.07.2015 Views

Guidelines for ATC classification and DDD assignment ... - WHOCC

Guidelines for ATC classification and DDD assignment ... - WHOCC

Guidelines for ATC classification and DDD assignment ... - WHOCC

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

- “Titrate up to a high dose if it is tolerated”: the high dose would normallybe chosen as the <strong>DDD</strong>.- “Consider to increase the dose only if efficacy is not satisfactory withinitial dose”: the <strong>DDD</strong> would normally be based on the initial dose.- For some groups of medicinal products specific principles <strong>for</strong> <strong>DDD</strong> <strong>assignment</strong>are established (e.g. the <strong>DDD</strong>s <strong>for</strong> the selective serotonin agonists in thetreatment of migraine are based on the approved initial dose). These principlesare given in the guidelines.- The treatment dose is generally used. If, however, prophylaxis is the mainindication, this dose is used, e.g. <strong>for</strong> fluoride tablets (A01AA01) <strong>and</strong> someantimalarials.- A <strong>DDD</strong> is usually established according to the declared content (strength) of theproduct. Various salts of a substance are usually not given different <strong>DDD</strong>s.Exceptions are described in the guidelines <strong>for</strong> the different <strong>ATC</strong> groups. Forexample, the <strong>DDD</strong>s <strong>for</strong> antimalarials are expressed as the base.- Normally, different stereoisomeric <strong>for</strong>ms are assigned separate <strong>DDD</strong>s <strong>and</strong> <strong>ATC</strong>codes. The <strong>DDD</strong>s <strong>for</strong> stereoisomeric <strong>for</strong>ms are described in the respective <strong>ATC</strong>groups.- Prodrugs, which have not been given a separate <strong>ATC</strong> code, are normally notgiven a separate <strong>DDD</strong>.- The <strong>DDD</strong> is often identical <strong>for</strong> various dosage <strong>for</strong>ms of the same drug. Different<strong>DDD</strong>s may be established when the bioavailability is substantially different <strong>for</strong>various routes of administration (e.g. oral <strong>and</strong> parenteral administration ofmorphine) or if the dosage <strong>for</strong>ms are used <strong>for</strong> different indications. When the useof parenteral <strong>for</strong>mulations represents only a minor fraction of the total use <strong>for</strong> aspecific indication, these products do not receive a separate <strong>DDD</strong> even if thebioavailability of the oral <strong>for</strong>m is substantially different.- Parenteral products with different routes of administration (e.g. i.v. <strong>and</strong> i.m.)have the same <strong>DDD</strong>.The <strong>DDD</strong> is nearly always a compromise based on a review of the availablein<strong>for</strong>mation including doses used in various countries when this in<strong>for</strong>mation isavailable. The <strong>DDD</strong> is sometimes a dose that is rarely if ever prescribed, becauseit is an average of two or more commonly used dose sizes.24

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!